Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 1
2017 1
2018 1
2020 5
2021 3
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study.
Gori S, Fabi A, Angiolini C, Turazza M, Salvini P, Ferretti G, Cretella E, Gianni L, Bighin C, Toss A, Zamagni C, Vici P, De Rossi C, Russo A, Bisagni G, Frassoldati A, Borgato L, Cariello A, Cappelletti C, Bordonaro R, Cinieri S, Modena A, Valerio M, Alvisi MF, De Simone I, Galli F, Rulli E, Santoni A, Nicolis F. Gori S, et al. Among authors: alvisi mf. Cancers (Basel). 2023 Oct 4;15(19):4852. doi: 10.3390/cancers15194852. Cancers (Basel). 2023. PMID: 37835546 Free PMC article.
Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
Guffanti F, Alvisi MF, Anastasia A, Ricci F, Chiappa M, Llop-Guevara A, Serra V, Fruscio R, Degasperi A, Nik-Zainal S, Bani MR, Lupia M, Giavazzi R, Rulli E, Damia G. Guffanti F, et al. Among authors: alvisi mf. Br J Cancer. 2023 Mar;128(7):1405. doi: 10.1038/s41416-023-02205-1. Br J Cancer. 2023. PMID: 36797359 Free PMC article. No abstract available.
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Colombo N, Tomao F, Benedetti Panici P, Nicoletto MO, Tognon G, Bologna A, Lissoni AA, DeCensi A, Lapresa M, Mancari R, Palaia I, Tasca G, Tettamanzi F, Alvisi MF, Rulli E, Poli D, Carlucci L, Torri V, Fossati R, Biagioli E; BAROCCO study group. Colombo N, et al. Among authors: alvisi mf. Gynecol Oncol. 2022 Mar;164(3):505-513. doi: 10.1016/j.ygyno.2022.01.015. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063281 Clinical Trial.
Corrigendum to: Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Claudio Fantini M, Vecchi M, Geginat J, Caprioli F. Coletta M, et al. Among authors: alvisi mf. J Crohns Colitis. 2022 Jul 14;16(6):1010. doi: 10.1093/ecco-jcc/jjab107. J Crohns Colitis. 2022. PMID: 34850867 No abstract available.
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.
Buonfrate D, Chesini F, Martini D, Roncaglioni MC, Ojeda Fernandez ML, Alvisi MF, De Simone I, Rulli E, Nobili A, Casalini G, Antinori S, Gobbi M, Campoli C, Deiana M, Pomari E, Lunardi G, Tessari R, Bisoffi Z. Buonfrate D, et al. Among authors: alvisi mf. Int J Antimicrob Agents. 2022 Feb;59(2):106516. doi: 10.1016/j.ijantimicag.2021.106516. Epub 2022 Jan 6. Int J Antimicrob Agents. 2022. PMID: 34999239 Free PMC article. Clinical Trial.
"What if…": decisional regret in patients who discontinued active surveillance.
Repetto C, Rancati T, Magnani T, Alvisi MF, Avuzzi B, Badenchini F, Marenghi C, Stagni S, Maffezzini M, Villa S, Villa S, Salvioni R, Valdagni R, Bellardita L. Repetto C, et al. Among authors: alvisi mf. Tumori. 2016 Dec 1;102(6):562-568. doi: 10.5301/tj.5000564. Epub 2016 Sep 22. Tumori. 2016. PMID: 27716881
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
Ganzinelli M, Linardou H, Alvisi MF, Caiola E, Lo Russo G, Cecere FL, Bettini AC, Psyrri A, Milella M, Rulli E, Fabbri A, De Maglie M, Romanelli P, Murray S, Broggini M, Marabese M, Garassino MC. Ganzinelli M, et al. Among authors: alvisi mf. ESMO Open. 2021 Feb;6(1):100034. doi: 10.1016/j.esmoop.2020.100034. Epub 2021 Jan 7. ESMO Open. 2021. PMID: 33422766 Free PMC article.
Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F. Coletta M, et al. Among authors: alvisi mf. J Crohns Colitis. 2020 Sep 16;14(9):1190-1201. doi: 10.1093/ecco-jcc/jjaa035. J Crohns Colitis. 2020. PMID: 32100016 Clinical Trial.
16 results